Financhill
Buy
59

CNTA Quote, Financials, Valuation and Earnings

Last price:
$16.52
Seasonality move :
20.12%
Day range:
$14.96 - $16.64
52-week range:
$7.38 - $18.97
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
4.35x
Volume:
556.6K
Avg. volume:
581.1K
1-year change:
103.21%
Market cap:
$2.2B
Revenue:
$6.9M
EPS (TTM):
-$1.52

Analysts' Opinion

  • Consensus Rating
    Centessa Pharmaceuticals PLC has received a consensus rating of Buy. The company's average rating is a Buy based on 7 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
  • Price Target Upside
    According to analysts' consensus price target of $28.57, Centessa Pharmaceuticals PLC has an estimated upside of 73.58% from its current price of $16.46.
  • Price Target Downside
    According to analysts, the lowest downside price target is $24.00 representing 100% downside risk from its current price of $16.46.

Fair Value

  • According to the consensus of 7 analysts, Centessa Pharmaceuticals PLC has 73.58% upside to fair value with a price target of $28.57 per share.

CNTA vs. S&P 500

  • Over the past 5 trading days, Centessa Pharmaceuticals PLC has overperformed the S&P 500 by 5.87% suggesting its relative strength compared to the major market average is strong at this time.

Share Buyback

  • Centessa Pharmaceuticals PLC does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • Centessa Pharmaceuticals PLC has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Centessa Pharmaceuticals PLC reported revenues of --.

Earnings Growth

  • Centessa Pharmaceuticals PLC has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Centessa Pharmaceuticals PLC reported earnings per share of -$0.37.
Enterprise value:
1.7B
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-13.25x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
Trailing 12 Months Fiscal Quarters
Period Ending 2022-09-30 2023-09-30 2024-09-30 2023-09-30 2024-09-30
Income Statement
Revenue -- -- -- -- --
Gross Profit -- -- -- -- --
Operating Income -- -$177.7M -$161.7M -$40.2M -$46.4M
EBITDA -- -$174.1M -$147.2M -$38.7M -$39.2M
Diluted EPS -$2.54 -$1.64 -$1.52 -$0.40 -$0.37
Period Ending 2020-09-30 2021-09-30 2022-09-30 2023-09-30 2024-09-30
Balance Sheet
Current Assets -- $611.6M $477M $332.5M $568.4M
Total Assets -- $612.2M $479.4M $377.4M $609.7M
Current Liabilities -- $29.1M $38.2M $35M $26.4M
Total Liabilities -- $63.1M $106.4M $118M $110.6M
Total Equity -- $549.1M $372.9M $259.4M $499.1M
Total Debt -- -- -- -- --
Trailing 12 Months Fiscal Quarters
Period Ending 2022-09-30 2023-09-30 2024-09-30 2023-09-30 2024-09-30
Cash Flow Statement
Cash Flow Operations -- -$180.9M -$130.3M -$37.4M -$21.4M
Cash From Investing -- -$109.2M -$12M $48.7M $45M
Cash From Financing -- $14.8M $368.2M $14.7M $246M
Free Cash Flow -- -$181.6M -$130.4M -$37.4M -$21.4M
CNTA
Sector
Market Cap
$2.2B
$45.7M
Price % of 52-Week High
86.77%
47.48%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.75%
1-Year Price Total Return
103.21%
-32.34%
Beta (5-Year)
--
0.746
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Technicals

8-day SMA
Buy
Level $15.47
200-day SMA
Buy
Level $12.98
Bollinger Bands (100)
Buy
Level 14.96 - 17.26
Chaikin Money Flow
Buy
Level 6.5M
20-day SMA
Buy
Level $16.44
Relative Strength Index (RSI14)
Buy
Level 50.86
ADX Line
Sell
Level 21.26
Williams %R
Neutral
Level -43.2584
50-day SMA
Sell
Level $16.83
MACD (12, 26)
Sell
Level -0.41
25-day Aroon Oscillator
Sell
Level -68
On Balance Volume
Neutral
Level 10.3M

Financial Scores

Sell
Altman Z-Score (Annual)
Level (0.2929)
--
CA Score (Annual)
Level (--)
--
Beneish M-Score (Annual)
Level (--)
Buy
Momentum Score
Level (10)
--
Ohlson Score
Level (--)
--
Piotroski F Score (Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)

Revenue Forecast

Earnings per Share Forecast

Company Profile

Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include 1) SerpinPC for Hemophilia A, B, 2) LB101 for Solid Tumors, 3) ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders, 4) MGX292 Pulmonary Arterial Hypertension (PAH) and 5) Undisclosed for Solid Tumors.

Stock Forecast FAQ

In the current month, CNTA has received 7 Buy ratings 0 Hold ratings, and 0 Sell ratings. The CNTA average analyst price target in the past 3 months is $28.57.

  • Where Will Centessa Pharmaceuticals PLC Stock Be In 1 Year?

    According to analysts, the consensus estimate is that Centessa Pharmaceuticals PLC share price will rise to $28.57 per share over the next 12 months.

  • What Do Analysts Say About Centessa Pharmaceuticals PLC?

    Analysts are divided on their view about Centessa Pharmaceuticals PLC share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Centessa Pharmaceuticals PLC is a Sell and believe this share price will drop from its current level to $24.00.

  • What Is Centessa Pharmaceuticals PLC's Price Target?

    The price target for Centessa Pharmaceuticals PLC over the next 1-year time period is forecast to be $28.57 according to 7 Wall Street analysts, 7 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.

  • Is CNTA A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for Centessa Pharmaceuticals PLC is a Buy. 7 of 7 analysts rate the stock a Buy at this time.

  • How Can I Buy Shares Of CNTA?

    You can purchase shares of Centessa Pharmaceuticals PLC via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Centessa Pharmaceuticals PLC shares.

  • What Is The Centessa Pharmaceuticals PLC Share Price Today?

    Centessa Pharmaceuticals PLC was last trading at $16.52 per share. This represents the most recent stock quote for Centessa Pharmaceuticals PLC. Yesterday, Centessa Pharmaceuticals PLC closed at $16.46 per share.

  • How To Buy Centessa Pharmaceuticals PLC Stock Online?

    In order to purchase Centessa Pharmaceuticals PLC stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Philip Morris Stock Overvalued?
Is Philip Morris Stock Overvalued?

If there is one industry that can be termed truly…

What Quantum Stocks Should I Buy?
What Quantum Stocks Should I Buy?

The last several years have seen a series of tech…

Will Sirius XM Be a 10-Bagger Stock?
Will Sirius XM Be a 10-Bagger Stock?

Last year, Warren Buffett surprised practically everyone when he acquired…

Stock Ideas

Buy
52
Is NVDA Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 118x

Sell
43
Is AAPL Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 37x

Buy
51
Is MSFT Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 36x

Alerts

Sell
32
FTAI alert for Jan 22

FTAI Aviation [FTAI] is up 3.9% over the past day.

Sell
2
EDU alert for Jan 22

New Oriental Education & Technology Group [EDU] is down 0.19% over the past day.

Buy
51
GH alert for Jan 22

Guardant Health [GH] is up 6.58% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock